Implanted bioengineered livers have not exceeded three days of continuous perfusion. Here we show that decellularized whole porcine livers revascularized with human umbilical vein endothelial cells and implanted heterotopically into immunosuppressed pigs whose spleens had been removed can sustain perfusion for up to 15 days. We identified peak glucose consumption rate as a main predictor of the patency of the revascularized bioengineered livers (rBELs). Heterotopic implantation of rBELs into pigs in the absence of anticoagulation therapy led to sustained perfusion for three days, followed by a pronounced immune responses directed against the human endothelial cells. A 10 day steroid-based immunosuppression protocol and a splenectomy at the time of rBEL implantation reduced the immune responses and resulted in continuous perfusion of the rBELs for over two weeks. We also show that the human endothelial cells in the perfused rBELs colonize the liver sinusoids and express sinusoidal endothelial markers similar to those in normal liver tissue. Revascularized liver scaffolds that can maintain blood perfusion at physiological pressures might eventually help to overcome the chronic shortage of transplantable human livers.
L iver transplantation is the only treatment for end-stage liver disease, although a chronic shortage of viable donor organ material continues to limit the number of life-saving liver transplants that can be performed. Recent advances in tissue engineering methods have accelerated the development of bioengineered organs as an alternative source of donor material, although the challenge of developing functional vasculature to support cellular metabolism, gas exchange and sustained perfusion in vivo has remained a major barrier to the clinical translation of these technologies 1 . Bioengineered liver (BEL) constructs have been created through the recellularization of acellular liver scaffolds and demonstrated in vitro functionality [2] [3] [4] [5] [6] [7] [8] . Short-term in vivo function has also been reported following transplantation in small animal models 9 , although rapid vascular thrombosis limited the duration of in vivo graft patency. Passivation methods and high doses of anticoagulants have been employed to extend the in vivo patency of BELs, although these approaches only modestly extended thromboresistance 6, 10, 11 . No reported methods demonstrated a capacity to exceed three days of continuous BEL perfusion in vivo.
Decellularized whole liver matrix holds great potential as a technology for developing a theoretically limitless supply of functional BELs 12, 13 . While several groups demonstrated an ability to seed a variety of liver-specific cell types into decellularized liver constructs 12, [14] [15] [16] , reconstituting the endothelial cell lining within the vascular networks in these scaffolds remained an important challenge in the development of a therapeutic BEL 17 .
Here we report an optimized method for revascularizing a clinically scaled porcine liver scaffold. Using human umbilical vein endothelial cells (HUVECs) as a primary cell source, we characterized the kinetics of endothelial cell proliferation in decellularized liver scaffolds during perfusion bioreactor culture and identified glucose consumption rate (GCR) as a reliable metric for non-destructively monitoring cell proliferation and ultimately predicting graft patency following acute blood perfusion. Histological characterization of revascularized BELs (rBELs) revealed that HUVECs localized within sinusoidal regions upregulated the expression of LYVE1 and downregulated CD31 expression over time, suggesting a transition towards a liver sinusoidal endothelial cell (LSEC)-like phenotype. Transcript analysis of rBEL samples revealed global changes in gene expression in grafts with high GCRs, including the upregulation of additional LSEC markers, and transmission electron microscopy (TEM) revealed the existence of fenestra-like structures in endothelial cells localized within sinusoidal regions. Finally, up to 15 days of continuous in vivo rBEL perfusion was achieved under a steroid-based immunosuppression protocol following heterotopic implantation in a large animal liver transplant model. Characterization of the recipient animal immune response following graft implantation revealed the presence of HUVEC-reactive antibodies and identified complement activation as a likely driver
Results
Liver decellularization and perfusion bioreactor culture. The porcine livers used in this study were cannulated on the portal vein (PV), infrahepatic inferior vena cava (IVC) and suprahepatic vena cava (SVC) and decellularized by sequential perfusion with Triton X-100 solutions and sodium dodecyl sulphate (SDS) solutions to remove cellular material while preserving the overall architecture of the scaffold (Fig. 1a,b,e ). Histological sectioning from representative decellularized scaffolds confirmed the maintenance of parenchymal liver lobule structures when compared to that of native porcine liver tissue (Fig. 1c,f) , as well as the retention of Collagen I (Fig. 1d,g) .
Decellularized liver scaffolds were mounted in custom bioreactors ( Fig. 1h ,i) and perfused with culture media through the SVC at a constant inflow pressure of 12 mm Hg at 37 °C and 5% CO 2 . Following 72 h of continuous media perfusion to precondition the scaffold and confirm the absence of viable bioburden, 1.5 × 10 8 HUVECs were infused through the perfusion circuit into the SVC vasculature ( Fig. 2a ). Following 24 h of continuous media perfusion, liver scaffolds were aseptically manipulated and infused with an additional 1.5 × 10 8 HUVECs through the PV ( Fig. 2a ). Before seeding, the purity of the HUVEC cultures was confirmed by CD31+ flow cytometry ( Fig. 2b) . Culture media was continuously perfused through the PV at 12 mm Hg for the remaining period of bioreactor culture.
Characterization of HUVEC proliferation. To define quantitative markers for the non-invasive monitoring of endothelial cell proliferation in the liver scaffold, a panel of metabolites (glucose, lactate, glutamate and ammonia) were measured daily from a sample of rBEL culture media (data not shown). GCRs measured throughout the period of bioreactor culture exhibited sigmoidal kinetics in most rBELs and could be generally characterized by low (<20 mg h −1 ), mid (20-45mg h −1 ) and high (>45 mg h −1 ) GCR phases ( Fig. 2c ). Histological examination of representative rBELs with low, mid and high GCRs correlated with increasing endothelial cell densities as inferred from haemotoxylin and eosin (H&E) staining, with evidence of primary engraftment in larger vessels and subsequent expansion and migration into the parenchymal or sinusoidal niche at mid and high GCRs ( Fig. 2d-f ). As a result, rBEL GCRs were used as a metric for estimating the extent of graft re-endothelialization in later parts of this study. During bioreactor culture, media volumes were adjusted and replaced daily to maintain steady state glucose levels above 500 mg l −1 (>50% of baseline media concentrations) to ensure consistent proliferation kinetics and discourage premature cell senescence due to glucose starvation 18 . Two rBELs failed to exhibit sigmoidal kinetics or achieve a GCR >20 mg h −1 ( Fig. 2c ) and demonstrated similar proliferation kinetics to substantially underseeded rBELs (data not shown), which was probably a result of an undetected hole in the PV or hepatic vein during seeding.
Phenotypic plasticity of HUVECs in rBELs.
Immunostaining of rBELs during low, mid and high GCR phases with anti-CD31 and anti-Collagen I antibodies ( Fig. 2g -i, Supplementary Fig. 1a ) revealed HUVEC localization within vascular structures and overall uniform cell distribution within the decellularized liver matrix. Endothelial cell engraftment was primarily localized within larger vessels during the low GCR phase following seeding, followed by an increase in cell liver decellularization and perfusion bioreactor system. a, Native porcine livers were cannulated on the PV, IVC and SVC and decellularized by sequential perfusion with Triton X-100 and SDS solutions. b, Representative photograph of a native porcine liver. c,d, H&E staining (c) and collagen I immunofluorescence (d) of native liver tissue. e, Representative photograph of a decellularized porcine liver. f,g, H&E staining (f) and collagen I immunofluorescence (g) of decellularized liver tissue. h,i, A schematic (h) and photo (i) of a perfusion bioreactor system comprising a custom bioreactor and a pressure-dependent perfusion control system. The bioreactor includes a pressure transducer (PT) to monitor perfusion pressure, a gas exchange coil (GEC) to allow efficient gas exchange during media perfusion, a bubble trap (BT) to prevent the introduction of bubbles into the rBEL, a 0.22 μm filter air vent (AV) and three-way stopcocks (3W) to enable media exchange and sampling. DAPI, 4,6-diamidino-2-phenylindole; P, pump.
proliferation within sinusoidal regions at mid and high GCR phases. Immunostaining for LYVE1, a marker expressed by LSECs, demonstrated that the highest expression was in the parenchymal sinusoids with low expression in larger vessels ( Fig. 2k -m, Supplementary  Fig. 1b ), which is consistent with native liver sinusoid staining 19 . The expression and localization of LYVE1 was weakly detected during the low GCR phase and became progressively stronger in the mid and high GCR phases. Transcript levels of LSEC-associated markers measured by quantitative PCR with reverse transcription (qRT−PCR) in the high GCR phase demonstrated an upregulation of LYVE1 (7.2-fold ± 1.8-fold, n = 7, mean ± s.d.) and STAB2 (4.8fold ± 3.31-fold, n = 7) compared to HUVEC cells cultured in standard two dimensional culture flasks, as well as a significant increase from low to high phases (P < 0.05) for LYVE1, while CD31 was not significantly changed (1.9-fold ± 1.8-fold, n = 7; Fig. 1j ). Global characterization of rBEL samples from low and high GCR phases through RNA-sequencing (RNA-seq) analysis revealed significant changes in gene expression profiles over time as demonstrated by a global principal component analysis ( Fig. 2n ) and targeted similarity analysis using known liver endothelial cell markers 20 ( Fig. 2o , Supplementary Dataset 3). Further analysis of the RNA-seq datasets confirmed upregulation of LYVE1 and also showed downregulation of VWF and upregulation of ICAM1 in high GCR samples ( Fig. 2p ), revealing additional expression trends that resemble recently reported primary human LSEC transcript profiles 20 .
A hallmark feature of LSECs in normal liver tissue is the presence of plasma membrane fenestrations that enable the diffusion of nutrients and waste products between the capillary vessels and the adjacent parenchymal space. To determine whether endothelial cells localized within sinusoids of rBEL constructs exhibited such features, TEM was performed on samples from native porcine liver tissue ( Fig. 2q ) and high GCR phase rBELs ( Fig. 2r -t). Micrographs from rBELs exhibited fenestra-like structures similar to those observed in native porcine liver sections. The quantified dimensions of these features were consistent with those of LSEC fenestrations (100−150 nm) 21 . Collectively, these results reveal a new dimension of HUVEC phenotypic plasticity 22, 23 and suggest that distinct microenvironments in decellularized liver matrix may have the capacity to direct phenotypic differentiation of endothelial cells.
Peak GCR (PGCR) in rBELs correlates with patency. To assess the patency of rBELs, an ex vivo blood loop circuit using fresh heparinized porcine blood was employed ( Fig. 3a,b ). Using a peristaltic pump, prewarmed blood (37 °C) was perfused through the PV of the rBEL and returned to the blood reservoir following outflow from the IVC. Perfusion was maintained at a constant pressure of 12 mm Hg and flow rates were monitored over time. Flow rates <50 ml min −1 after 30 min were deemed inadequate for in vivo perfusion. Evaluation of non-seeded decellularized liver scaffolds consistently resulted in flow rates <10 ml min −1 after 5 min and had zero flow after 15 min (data not shown). PGCR is the maximum GCR measured during BEL culture; rates >30 mg h −1 in rBELs correlated with sustained flow rates >50 ml min −1 , thereby validating the use of the PGCR as a marker for the functional re-endothelialization of rBELs (n = 5; Fig. 3k ). Histological evaluation of low glucose consuming grafts following blood perfusion and saline flushing showed blood pooling and compaction within the graft, while grafts with PGCRs >30 mg h −1 were efficiently cleared with saline ( Supplementary Fig. 2 ).
To determine the value of PGCR in predicting rBEL patency in vivo, a large animal porcine model for auxiliary liver transplantation was established to enable the implantation and patency assessment of rBELs (n = 5). To this end, rBELs were implanted with end-to-side anastomoses between the graft's PV and recipient pig's PV ( Fig. 3c -i). Before perfusing the rBELs, portal branches supplying the pig's native liver were tied off preserving the first portal branch supplying the caudate lobe and the right lateral lobe. A constriction ribbon was also applied to the pig's PV distal to the anastomosis to partially bias flow through the rBEL. These measures were taken to raise the portal pressure and facilitate preferential blood flow to the implanted rBELs. The PV surgical model provided mean venous pressure of 8.4 ± 2.2 mm Hg (n = 5; mean ± s.d.) and mean blood flow rates of 414 ± 16.7 ml min −1 (n = 5; mean ± s.d.). rBELs were implanted and monitored for 30 min with inflow and outflow confirmation via Doppler ultrasound ( Fig. 3j ). Vascular perfusion was assessed 30 min after anastomosis by direct volumetric measurement of outflow blood for 60 s. The blood was subsequently returned to the circuit. PGCR >30 mg h −1 demonstrated >100 ml min −1 of perfusion after 30 min in three of four rBELs ( Fig. 3k ) further confirming the correlation between PGCR and in vivo graft patency.
Long-term in vivo perfusion in an immunosuppressed porcine liver transplant model.
To assess long-term patency in vivo, rBELs were implanted using the previously described auxiliary liver transplantation model ( Fig. 3b , Supplementary Movie 1) and recipient animals were recovered without the addition of postoperative antiplatelet or anticoagulation therapies. To determine the impact of a host immune response directed towards the HUVEC component of the rBELs on eventual graft failure, recipient animals were divided into two cohorts (n = 4 per condition). One group underwent an immunosuppressive therapy regimen and the other received no additional treatment (excluded were three additional non-immunosuppressed implants and one additional immunosuppressed implant that experienced immediate (within 24 h) graft loss attributable to surgical complications). In the immunosuppressed group, before rBEL implantation, surgical splenectomy was performed and intravenous methylprednisolone was administered at 500 mg with subsequent daily doses of 500, 250, 250, 125, 125, 80, 60, 40, 30 and 20 mg ( Fig. 4a ). Computed tomography (CT) imaging with intravenous contrast was performed postoperatively on days 0, 1, 3, 7, 10, 15 and . d−i, PGCRs correlated with total endothelial cell coverage as characterized by H&E staining (d (low), e (mid), f (high)) and anti-CD31 immunostaining (g (low), h (mid), i (high)). j, qRT−PCR analysis of CD31, LYVE1 and STAB2 mRNA levels in rBELs harvested at low (n = 4), mid (n = 4) and high (n = 7) glucose consumption phases. Data are plotted as fold change relative to HUVECs in 2D culture. Individual values represent biological replicates. Mean values ± s.d. are shown. Statistical significance was determined using a one-way analysis of variance (ANOVA) test from delta cycle threshold (ΔCT) values before fold-change normalization. k-m, CD31 and LYVE1 immunostaining from rBELs harvested at low (k), mid (l) and high (m) glucose consumption phases. n, A principal component (PC) analysis of RNA-seq gene expression profiles from rBELs harvested at low (n = 2 biological replicates) and high (n = 6 biological replicates) glucose consumption phases. o, A similarity matrix of BEL samples from n comparing low and high glucose consumption phase rBEL samples with respect to a panel of known liver endothelial cell markers (input genes: F8, CD31, STAB2, LYVE1, CD14, VWF, ENG and ICAM1). p, RNA-seq expression profiles for liver sinusoidal endothelial markers LYVE1, VWF and ICAM1 in low (n = 2) and high (n = 6) glucose consumption phase rBEL samples. HUVECs (n = 1) and primary human LSECs (HLSECs; n = 1) cultured in 2D are included for comparison. Biological replicates are plotted along with the mean ± s.d. q-t, TEM images from native liver (q) and rBEL (r-t) samples. Red arrows indicate fenestra-like structures within endothelial cells. 20 to assess the extent of perfusion through the rBELs (Fig. 4a -c). Perfusion following each CT imaging time point was quantified using CT volumetric measurements using Siemens MultiModality Workstation. Graft volume was manually marked and the perfused area was autodetected using the Hounsfield threshold cut-off. Threedimensional (3D) reconstruction was performed using TeraRecon medical imaging software with the assistance of 3D visualizations created using Analyze (ref. 24 ; Fig. 4b , Supplementary Movie 2).
The percentage reduction in perfusion of the rBELs from the baseline postoperative CT scan was calculated and plotted ( Fig. 4d , Supplementary Fig. 4 ). In the absence of immunosuppression, all four implanted rBELs lost >85% of their initial perfusion by day 7 post-transplant. By contrast, the immunosuppressed group had significantly longer graft perfusion and vascular patency when compared to the group without immunosuppression: 8.5 d (7-15 d) (median (range)) versus 3 d (1-7 d), P = 0.037, and 11 d (7-20 d) Table 1) . Complete blood count, liver function, renal function and coagulation factors were followed preoperatively and at postoperative days 1, 3, 7, 10, 15 and 20 (Supplementary Table 2 ). One rBEL was harvested from an immunosuppressed recipient animal at day 7 for histological analysis, demonstrating the persistence of the HUVEC populations in the graft ( Supplementary Fig. 3a,b ). The other three grafts were monitored by CT imaging until the total loss of graft perfusion, which was observed on days 10, 15 and 20, respectively. Total loss of portal-venous flow was seen on days 10 and 20 while one graft continued to have some portal-venous flow through the graft despite total loss of parenchymal perfusion (Fig. 4d ). Evidence of rBEL perfusion was present in all of the grafts in the immunosuppressed group at day 7, demonstrating a significant increase in sustained perfusion over the non-immunosuppressed group (P = 0.01).
Early immune response to rBEL xenotransplantation. The native pig immune response to HUVEC cells was characterized to confirm whether the high rate of graft failure between days 3 and 7 was associated with an immune response to the HUVECs used to revascularize the rBELs. Pig serum was collected at each CT scan and incubated with HUVEC cultures to perform a complement-mediated cytotoxicity assay 25 . The complement-mediated cytotoxicity reaction was observed in naive pig sera and HUVECs at the baseline (range: 30-85% cell death) demonstrating an inherent immune response to the human-derived cells without graft exposure in both the no treatment and immunosuppressed groups (Fig. 4e ). Evidence of in vivo complement activation was observed by C4D deposition on endothelial cells in explanted rBEL samples ( Supplementary Fig. 3c) .
Cytotoxicity significantly increased in the untreated group by day 3 (81.7 ± 21.0; mean ± s.d.) and remained at >98% following day 3. By contrast, immunosuppression significantly reduced cytotoxicity at day 1 and day 3 (25.2% ± 29.4% and 8.68% ± 8.49%, respectively) followed by a notable increase in cytotoxicity at day 7 (84.7% ± 13.0%) and >98% cytotoxicity at day 10 and day 15 (Fig. 4e ). rBEL perfusion in the no treatment and immunosuppressed groups correlated to cytotoxicity responses. Decreased rBEL perfusion was preceded by a significant increase in immune response as seen on day 3 for the untreated group and day 7 for the immunosuppressed group (Fig. 4d,e ).
Discussion
The only cure for end-stage liver disease, the eighth most frequent cause of death in the United States, is liver transplantation. Unfortunately, the demand for transplantable donor livers continues to exceed the available supply and, as a result, only half of the 11,000 wait-listed patients will receive transplants 26 . Globally, it is estimated that over one million patients could benefit from a liver transplant 27 . The insufficient supply of transplantable donor livers underscores the need for alternative strategies to generate functional liver tissue for patients suffering from liver failure.
Efforts to overcome the chronic shortage of transplantable human livers include attempts at alternative organ procurement and replacement strategies 28 . Xenogeneic whole organ transplantation promises a theoretically limitless supply of donor organ material, but immunological incompatibility, fundamental differences in basal metabolism between humans and other species and coagulopathy remain substantially translational barriers 6, 17, 29 . Hepatocyte transplantation is an approved alternative to whole organ replacement; however, due to poor cell engraftment efficiency and deterioration of cell function over time, it is mostly used as a bridge therapy and temporary metabolic support ahead of whole liver transplantation 30 . Tissue engineering remains a promising solution to the chronic organ shortage but has been significantly inhibited by the lack of functional vasculature required to support the implantation of engineered tissue similar to donor grafts. Whole organ perfusion decellularization and recellularization technologies have demonstrated the ability to maintain the native architecture and have demonstrated organ function from the recellularization of liver 6,31,32 , kidney 33, 34 and lung 35 . However, none have demonstrated the ability to sustain long-term in vivo perfusion; this is due to incomplete restoration of the vasculature, which is a critical issue to solve to move the field forward.
The daily measurement and analysis of metabolic markers, specifically daily GCRs, provided the opportunity for critical adjustments for bioreactor media volume and provided growth parameters that were evaluated as surrogates for re-endothelialization. PGCR not only indicates the level of rBEL endothelialization in culture 36 but is also predictive of in vivo performance. The resulting function of the rBEL was independent of days in culture, but instead dependent on metabolic activity. It appears that these phases correlated with increased endothelial coverage starting in the larger vessels followed by proliferation and migration into the parenchymal space during mid and high GCR phases. The defined PGCR levels were characterized for 250 to 350 g livers and it is expected that moving to larger livers will require a higher minimum PGCR threshold.
During this time, LYVE1 expression and localization was increased in the parenchymal space, with little expression in larger vessels. The inverse was observed with the localization of CD31, suggesting a degree of phenotypic plasticity of HUVECs within the decellularized liver scaffold. Global gene expression via RNAseq analysis on isolated rBEL sections characterized a shift in gene expression between low and high glucose consuming rBELs and revealed additional gene expression trends consistent with an LSEC-like phenotype. To provide physical evidence of fenestrations, a key hallmark of LSECs, TEM evaluation of rBELs exhibited fenestra-like features that were similar in size to those observed in native liver sections. The combined molecular analysis and microscopic examination support the shift towards an LSEC-like phenotype and will need to be further characterized following the addition of hepatocytes and cholangiocytes to the rBELs.
To assess the deleterious effects of a host immune response to human cells, the xenocompatibility phenomenon between pig serum and human cells was investigated. A non-sophisticated 10 d immunosuppression protocol was used to demonstrate the ability to increase the vascular perfusion of the rBELs from, on average, 3.5 d up to 15 d and extend the patency of the vascular tree beyond 15 d. The immunosuppression protocol used in this study was not intended to provide long-lasting immunosuppression, but rather to determine whether a species-dependent immunological response was contributing to the loss of graft perfusion. Vascular patency was prolonged using the immunosuppression regimen indicating that xenoincompatibility played an important role in eventual rBEL thrombosis in vivo. Following immunosuppression withdrawal, similar kinetics for graft thrombosis to the non-immunosuppressed group were observed. Vascular patency in the humanized BEL grafts would have probably been sustained for longer with continued immunosuppressive therapy.
In this study, we demonstrate an ability to produce rBEL constructs with functional vasculature that can retain long-term in vivo vascular patency leading to definitive functional testing of coseeded whole liver grafts with parenchymal hepatocytes and cholangiocytes. Adequate endothelialization is sufficient to prevent vascular thrombosis, thus providing a path forwards to engineer a fully functional transplantable liver.
Methods
Decellularization of porcine livers. Whole livers (250 to 350 g) were excised from cadaveric pigs. The SVC, IVC, PV and bile duct were cannulated and flushed with 150 ml sterile saline. The cannulated livers were perfusion decellularized with 1× Triton X-100 (Amresco, M143) for 2-5 h followed by 0.6% SDS (Amresco, 0227) for 4-8 h at a perfusion pressure maintained between 8-12 mm Hg. The decellularized livers were disinfected with 1,000 ppm peracetic acid (US Water, BI0032-6). The decellularized grafts were washed with PBS (Corning 21-040-CMX12) and stored. All decellularization was completed in an ISO 7 cleanroom. Decellularization and recellularization used a custom-built perfusion system to automatically adjust flow to maintain a defined pressure using Cole−Palmer peristaltic pumps (7575-30, 77200-60).
HUVEC cell culture and seeding of decellularized liver constructs. HUVECs (Lonza, C2517A) were cultured in antibiotic-free EGM-2 (Lonza, CC-3162) medium in tissue culture flasks (Falcon) at 37 °C and 5% CO 2 and passaged with 0.25% trypsin (Thermo Fisher Scientific, 25200056) at 90-100% confluency according to the manufacturer's protocol. The highest passage used for seeding liver grafts was passage 11.
The medium used for HUVEC culture was also used for seeding and maintaining revascularized liver constructs in this study. Decellularized porcine livers were placed in a custom bioreactor containing 800 ml media, connected to the perfusion inlet via the SVC and perfused at 12 mm Hg with culture media before seeding. 1.5 × 10 8 HUVECs were resuspended in 100 ml media and seeded through the SVC followed by 50 ml of fresh media to clear the measured tubing void volume. The infused cell suspension was left under static conditions for 1 h and then continuous perfusion was restarted. After 24 h, perfusion was changed from the SVC to the PV and the seeding protocol was repeated with an additional 1.5 × 10 8 HUVECs. Re-endothelialized grafts were maintained in a continuous perfusion loop; the metabolites (glucose, lactate, glutamine, glutamate and ammonia) were monitored daily in collected media samples using a BioProfile FLEX analyser (Nova Biomedical). The culture media was exchanged and the volume increased depending on the rate of glucose depletion in the circulating medium to ensure 24 h glucose levels above 500 mg l −1 . All liver bioreactors were cultured in a humidified 37 °C incubator with 5% CO 2 .
Histological analysis. The tissue samples analysed in this study were perfused with PBS and fixed with 10% neutral buffered formalin (VWR 16004-128). Fixed tissues were paraffin embedded, sectioned and stained using standard histologic techniques. Immunofluorescence slides were deparaffinized and rehydrated; retrieval was performed in citrate buffer, pH 6.0 (Abcam AB93678) in a programmable decloaker (Biocare DC2012). Slides were permeabilized with PBS + 0.05% Tween-20 (Sigma P9416) and blocked with Sea Block (Thermo Fisher Scientific 37527). Primary antibodies used included mouse anti-CD31 (Abcam AB187377), rabbit anti-Collagen I (Abcam AB34710), rabbit anti-LYVE1 (Abcam AB33682) and mouse anti-C4D (Abcam AB90804). Secondary antibodies used were goat antirabbit Alexa Fluor 488 (Thermo Fisher Scientific A11078), goat antimouse Alexa Fluor 488 (Thermo Fisher Scientific A11029) and goat antirabbit Alexa Fluor 555 (Thermo A21429). Slides were stained with 4,6-diamidino-2-phenylindole (Thermo Fisher Scientific D1306) diluted 1:200 in PBS and mounted using ProLong Antifade Mountant (Thermo Fisher Scientific P36961). Fluorescence slides were imaged on a Zeiss Axioskop 40 and H&E slides were imaged on an Accuscope 3012.
TEM.
Tissue was fixed with 4% paraformaldehyde + 1% glutaraldehyde fix in PBS, pH 7.2. Following fixation, cells were stained with 1% osmium tetroxide and 2% uranyl acetate, dehydrated through an ethanol series and embedded into Embed 812 resin. After a 24 h polymerization at 60 °C, 0.1 µm ultrathin sections were poststained with lead citrate. Micrographs were acquired using a JEOL1400+ transmission electron microscope (Peabody, MA) operating at 80 kV with a Gatan Orius camera and Digital Micrograph software (Pleasanton, CA).
RNA extraction and qRT−PCR. RNA isolation was performed using TRIzol Reagent (Thermo Fisher Scientific) and transcribed to complementary DNA using the Superscript III First-Strand Synthesis System (Invitrogen). Gene expression analysis was performed using the Platinum SYBR green qRT−PCR supermix-UDG kit (Invitrogen) in a ViiA 7 Real-Time PCR instrument (Thermo Fisher Scientific). Ribosomal protein L19 (RPL19) was used as a housekeeping gene for normalization. The following primer sets were used in this study: RPL19 5′-ATTGGTCTCATTGGGGTCTAAC-3′, 5′-AGTATGCTCAGGCTTCAGAAGA-3′; STAB2 5′-GCAAGAAGATGTGATAGGAAGTCTC-3′, RNA-seq analysis. Tissue samples from low GCR (n = 2) and high GCR (n = 6) rBELs, along with HUVECs (n = 1) and human LSECs (Cell Systems, ACBRI 566; n = 1) were processed for RNA-seq analysis. RNA isolation was performed using TRIzol Reagent (Thermo Fisher Scientific). Messenger RNA isolation for all samples was performed using the Direct-zol RNA Miniprep Kit (Zymo Research) and quantified using a NanoDrop 2000 spectrophotometer (Thermo Fisher Scientific).
Samples were assessed for RNA integrity using the Agilent Bioanalyzer DNA 1000 chip (Invitrogen). Only samples with RNA integrity scores >6 and DV 200 > 50% were selected for sequencing. RNA-seq and subsequent primary and secondary data analysis were performed as previously described 37, 38 . In brief, library preparation was performed using the TruSeq RNA library preparation kit (Illumina). Polyadenylated mRNAs were selected using oligo dT magnetic beads. TruSeq Kits were used for indexing to permit multiplex sample loading on the flow cells; paired-end sequencing reads were generated on the Illumina HiSeq 2000 sequencer. Quality control for concentration and library size distribution was performed using an Agilent Bioanalyzer DNA 1000 chip and Qubit fluorometry (Invitrogen). The sequence alignment of reads and the determination of normalized gene counts were performed using the MAP-RSeq (v.1.2.1) workflow, using TopHat 2.0.6 (ref. 39 ) and HTSeq (v.0.11.1) (ref. 40 ). Normalized read counts were expressed as reads per kilobase pair per million mapped reads.
All genes with an average expression >0.3 reads per kilobase pair per million mapped reads in at least one group (n = 12,944) were used for subsequent analyses. Principal component analysis was performed using the ClustVis (12/20/2018 update) online tool 41 . Similarity matrix and hierarchical clustering analyses were performed using Morpheus matrix visualization and analysis (Morpheus, https:// software.broadinstitute.org/morpheus, Broad Institute). Functional annotation and Gene Ontology (GO) term enrichment scores were calculated using DAVID Bioinformatics Resources 6.8 database (DAVID 6.8) 42 . Results from the DAVID analysis (Supplementary Dataset 1), a list of upregulated genes (Supplementary Dataset 2) and a list of input genes used for the similarity matrix analysis ( Supplementary Dataset 3) are included in the Supplementary Materials.
Acute blood flow studies. For in vitro blood perfusion studies, each rBEL was connected to a circuit composed of silicone tubing, a pressure transducer and a peristaltic pump. The recirculation of freshly harvested, 37 °C heparinized porcine blood was targeted at 9-12 mm Hg to mimic maximum physiologically achievable venous pressure and the resulting flow rates were monitored over time.
In vivo acute blood studies were performed using domestic pigs weighing 30-35 kg. rBEL constructs were connected to the portal-venous blood flow using silicone tubing and Luer lock connectors to achieve functional end-to-side anastomoses between the graft's and recipient animal's PVs and IVCs. Luer lock connectors enabled the direct measurement of blood flow with and without the rBEL in the circuit. Flow was assessed by the direct measurement of collected outflow blood for 60 s, which was subsequently returned to the circuit. A post-test graft venogram through the PV was performed to ensure the patency of the portal vascular tree using 15-20 ml of Omnipaque 3000. Intravenous heparin was used to maintain an activated clotting time >600 s throughout the procedure.
Long-term studies to assess graft perfusion and vascular patency. Grafts with a GCR >30 mg h −1 were selected for transplantation in all long-term in vivo perfusion studies. All animal experiments were performed in accordance with the Animal Welfare Act and approved by the institutional animal care and use committee at the Mayo Clinic. Heterotopic implantation of rBELs in this study relied on end-to-side anastomoses between the graft's and recipient animal's PVs and the graft's and recipient animal's IVCs. All portal branches supplying the animal's native liver, with the exception of the first branch, were tied off, thus preserving blood flow to the caudate lobe and the right lateral lobe. Furthermore, a constricting ribbon was applied surgically around the native PV distal to the anastomosis to enhance blood flow to the implanted rBEL. This sequence was followed to elevate the PV pressure while avoiding haemodynamic instability resulting from host PV clamping and abrupt cessation of portal flow.
The surgical procedure was performed under normal haemostasis without the use of systemic heparinization. Side clamping of the pigs' PVs and vena cavas was performed to allow the anastomoses to be fashioned while minimizing the risk of thrombosis. After the procedure, the pigs were monitored in a recovery cage for the first 24 h and assessed every 4-6 h for any signs of bleeding or immediate surgical complications. Pigs were allowed to drink during this period as tolerated. Subsequently they were allowed to return to their regular housing and were allowed their regular diet as tolerated.
Operative data included operating room start and finish time, cold ischaemia time, activated clotting time, liver function test, complete blood count and coagulation factors. Cytotoxicity profiles were followed preoperatively and at postoperative days 1, 3, 7, 10, 15 and 20. To evaluate vascular patency and graft perfusion, contrast enhanced CT scans were performed serially postoperatively following the same time points listed above. All scans included a dedicated portalvenous phase taken 50-60 s after contrast infusion.
All pigs were followed until graft thrombosis was ascertained via contrast enhanced CT scans, except for one pig in the immunosuppressed group that was intentionally killed at postoperative day 7 to obtain histopathological graft data at that time.
Volumetric analysis of the graft perfusion and vascular patency of the large vessels was calculated using Siemens MultiModality Workstation-VA48A. Perfused areas were automatically detected using the Hounsfield density cut-off threshold. Subsequent loss of perfusion was calculated over time, at days 1, 3, 7, 15 and 20. Loss of graft perfusion was defined by the absence of notable perfusion outside the major portal branches and hepatic veins. The complete loss of perfusion and vascular patency was defined by a clear loss of flow in the graft's PV branches. Given the plasticity of the rBEL, the volume was affected in cases of ileus or gastric distension that sometimes occurred in the first 3-5 d after surgery.
Serum cytotoxicity assay. The complement-based cytotoxicity assay was adapted from a previously described protocol 25 . Briefly, 48-well tissue culture plates were seeded with 1 × 10 5 HUVECs per well and incubated at 37 °C until 80-100% confluence was reached (24-48 h). Following an initial PBS wash, pig sera were diluted 1:32 with EGM-2 media and 200 µl of diluted pig sera were added to each well. Following 30 min of incubation at room temperature, wells were washed with PBS; 200 µl of unabsorbed rabbit complement (Pel-Freez) diluted 1:16 with EGM-2 media was added to each well and incubated at room temperature for 1 h. 2 µl of 1% Fluoroquench (Thermo Fisher Scientific) was added for the fluoroscopic assessment of viable and nonviable cells. Cytotoxicity was characterized by the resulting percentage of nonviable cells.
Statistical analysis. IBM SPSS version 25 was used to conduct the statistical analysis. Descriptive data are presented as mean ± s.d. For subsets of data that did not meet normality tests, the median and range were used. Correlations between graft flow and metabolic parameters were statistically compared using binary correlation and linear logistic regression. Surgical model parameters, duration of graft perfusion and vascular patency between immunosuppressed and nonimmunosuppressed animals were compared using a Student's t-test. Alternatively, the Mann−Whitney test was used for subsets of data that were not normally distributed (those with a Shapiro−Wilk's test P < 0.05). Corresponding author(s): Scott Nyberg, Jeffrey Ross Last updated by author(s): Jul 15, 2019 Reporting Summary Nature Research wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Research policies, see Authors & Referees and the Editorial Policy Checklist.
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Data collection
No software was used for data collection. Data analysis SPSS 25 was used for data analysis.
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The main data supporting the results in this study are available within the paper and its Supplementary Information. The raw and analysed datasets generated during the study are available for research purposes from the corresponding authors on reasonable request.
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Sample size
Constrained by the IACUC principles of Refinement, Reduction and Refinement, 5 animals were used to confirm the in-vitro data. The animals underwent in-vivo graft testing, and the data are reported. 12 animals were approved for the immunosuppression part of the study; these animals were randomized (block randomization) into 2 groups. The data were reviewed and determined to be sufficient, and no further animals were requested.
Data exclusions Animals that suffered surgical complication or graft loss within 24 hours of the surgical procedure were excluded and labeled as technical failure (a total of 4 cases) .
Replication
Replication was based on the reported sample size and on repeating the studies at different times and liver grafts.
Randomization Block randomization prior to the surgical procedure was performed, aiming to achieve an equal number of animals in each group.
Blinding
Blinding was not relevant to this study given the nature of the implantation model and the use of CT imaging to quantitatively assess graft flow.
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Materials
Validation
Validation statements were confirmed in the literature from each manufacturer for the species it was tested on. In addition, we performed internal verification on native tissue to confirm the specificity and appropriate concentrations of the antibodies.
Eukaryotic cell lines
Policy information about cell lines
Cell line source(s)
Human Umbilical Vein Endothelial Cells (HUVECs) were purchased from Lonza; Human Liver Sinusoidal Endothelial Cells (LSECs) were obtained from Cell Systems (ACBRI 566) Authentication HUVEC cells were received with a Certificate of Analysis. We confirmed via flow cytometry at various passages that the purity was maintained.
Mycoplasma contamination
All cells were routinely tested for mycoplasma contamination, and the results were always negative.
Commonly misidentified lines (See ICLAC register)
No commonly misidentified cell lines were used in this study.
